Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET

ESMO Open(2025)10.1016/j.esmoop.2025.105061Source: DataRank Database

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET is a research paper published in ESMO Open (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.38)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Edoardo Crimini ORCID,V.R. Holla,Kenna Shaw ORCID,A M Doefler,E. Campbell

Live enrichment

PubMed:40460677 PMC:PMC12167085 OpenAlex:https://openalex.org/W4410959157

The University of Texas MD Anderson Cancer Center

Grant: P30 CA016672

NIH

Grant: 1UL1TR003167

NIH

Grant: UM1 TR0045906

National Institutes of Health

Grant: 3UL1TR003167-02S4

Center for Clinical and Translational Sciences (CCTS)

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

FWCI

0.38

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://www.esmoopen.com/action/showPdf?pii=S2059702925009305

publisherhttps://www.esmoopen.com/action/showPdf?pii=S2059702925009305

publisherhttps://api.elsevier.com/content/article/PII:S2059702925009305?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2059702925009305?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.esmoop.2025.105061

Fields of Study

Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasmsRetrospective StudiesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-retHigh-Throughput Nucleotide Sequencing

Keywords

Cancer researchMutationMedicineOncologyInternal medicineBiologyGeneticsGeneRetReal-worldBrafTargeted TherapiesPrecision OncologyTumor Mutational BurdenProto-Oncogene Proteins B-rafMaleAdultAged, 80 and overProto-Oncogene Proteins c-retHigh-Throughput Nucleotide SequencingMiddle AgedNeoplasmsHumansOriginal ArticleFemaleRetrospective StudiesAged